On December 9, 2025, Moleculin Biotech, Inc. (MBRX) entered into warrant exercise inducement offer letters with holders of existing warrants. The 8-K filing disclosed that the company offered reduced or current exercise prices in exchange for new warrants, generating aggregate gross proceeds of $6.8 million.

According to the filing, the inducement warrants have an exercise price of $6.63 per share. The company offered different terms for various warrant series: holders of Series C and D warrants received reduced exercise prices, while holders of certain Series F warrants could exercise at the current price of $6.3219 per share. The new warrants, designated as Series G warrants, were issued as consideration for the early exercise.

The 8-K filing, signed by Chief Financial Officer Jonathan P. Foster, includes three exhibits detailing the transaction. Exhibit 4.1 contains the form of the Series G inducement warrant, while Exhibits 10.1 and 10.2 provide the specific inducement letter forms for different warrant holders. The company has regulatory deadlines to file a Resale Registration Statement by January 8, 2026, and have it declared effective by February 9, 2026.